Bacillus Calmette-Guérin in the management of superficial bladder cancer.

Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer. Int J Endocrinol (2015) 0.78

Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Rev Vaccines (2015) 0.76

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol (1976) 4.37

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol (2000) 4.28

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol (2002) 4.08

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology (2004) 2.64

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol (1999) 2.03

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol (2005) 1.84

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol (1997) 1.73

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int (2001) 1.50

Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol (2003) 1.41

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol (1987) 1.10

Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol (1994) 1.10

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol (2004) 1.07

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int (2002) 1.02

Bladder carcinoma in situ in 2003: state of the art. Eur Urol (2004) 1.02

Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol (2002) 1.02

Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol (1996) 1.01

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol (1989) 1.00

Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer. Clin Exp Immunol (1999) 0.96

Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol (2000) 0.91

Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology (1999) 0.91

Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am (2005) 0.89

The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol (2001) 0.87

Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. ANZ J Surg (2004) 0.82

Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol (1990) 0.81

Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol (2000) 0.81

Optimal management of the T1G3 bladder cancer. Urol Clin North Am (2005) 0.81

Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology (1997) 0.78

Non-antibody immunotherapy of cancer. Curr Opin Immunol (1993) 0.77

Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol (1998) 0.77

Dorsal onlay buccal mucosa versus penile skin flap urethroplasty for anterior urethral strictures: results from a randomized prospective trial. J Urol (2007) 1.18

Management of vesicovaginal fistula: An experience of 52 cases with a rationalized algorithm for choosing the transvaginal or transabdominal approach. Indian J Urol (2007) 1.15

Is laparoscopic nephrectomy the preferred approach in xanthogranulomatous pyelonephritis? Urology (2006) 1.14

Inferior vena cava in urology: importance of developmental abnormalities in clinical practice. ScientificWorldJournal (2005) 1.09

Laparoscopic pyeloplasty with concomitant pyelolithotomy--is it an effective mode of treatment? Urol Int (2008) 1.09

Tubeless percutaneous nephrolithotomy--should a stent be an integral part? J Urol (2007) 1.06

Renal capsular block: a novel method for performing percutaneous nephrolithotomy under local anesthesia. J Endourol (2004) 1.06

Sigmoid vaginoplasty: long-term results. Urology (2006) 0.97

A comparison of kidney retrieval incisions in laparoscopic transperitoneal donor nephrectomy. Urol Int (2008) 0.89

Delayed presentation in posterior urethral valve: long-term implications and outcome. Urology (2008) 0.86

Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors. Int Urol Nephrol (2009) 0.82

Retroperitoneal ganglioneuroma presenting as right renal mass. Urology (2006) 0.82

Laparoscopic radical nephrectomy: a journey from T1 to very large T2 tumors. Urol Int (2009) 0.80

Laparoscopic pyeloplasty: a versatile alternative to open pyeloplasty. Urol Int (2009) 0.79

Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage. Indian J Cancer (2006) 0.77

Authors' reply. Indian J Urol (2007) 0.75

Prolene (mesh) bulbourethral sling in male incontinence. Indian J Urol (2007) 0.75

Percutaneous nephrolithotomy of a staghorn stone in thoracic ectopic kidney. Int J Urol (2007) 0.75